SNOA Sonoma Pharmaceuticals, Inc.
Healthcare$1.10+3.77%ClosedMarket Cap: $1.9M
As of 2026-05-25
Valuation
P/E (TTM)
—
PEG
—
P/B
0.55
P/S
0.11
EV/EBITDA
0.00
DCF Value
$-31.58
FCF Yield
-131.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
38.2%
Operating Margin
-15.6%
Net Margin
-19.0%
ROE
-85.9%
ROA
-24.7%
ROIC
-28.3%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q3 null | $4.3M | 37.9% | $-678.0K | $-819.0K | $— | — |
| Q2 null | $5.6M | 37.8% | $-337.0K | $-534.0K | $— | — |
| Q1 null | $4.0M | 36.5% | $-1.1M | $-1.2M | $— | — |
| Q4 null | $3.8M | 40.7% | $-656.0K | $-776.0K | $— | — |
| FY null | $14.3M | 38.2% | $-3.7M | $-3.5M | $— | — |
| Q3 null | $3.6M | 35.6% | $-1.0M | $-928.0K | $— | — |
| Q2 null | $3.6M | 38.0% | $-850.0K | $-610.0K | $— | — |
| Q1 null | $3.4M | 38.5% | $-1.2M | $-1.1M | $— | — |
| Q4 null | $3.4M | 31.7% | $-1.4M | $-1.1M | $— | — |
| FY null | $12.7M | 37.3% | $-4.7M | $-4.8M | $— | — |
| Q3 2024 | $3.1M | 46.5% | $-844.0K | $-866.0K | $-1.59 | — |
| Q2 2024 | $2.7M | 36.3% | $-1.2M | $-1.5M | $-2.87 | — |